Director, Franchise Analytics & Execution

Director, Franchise Analytics & Execution

Azurity Pharmaceuticals is a privately held, specialty pharmaceutical company that focuses on innovative products that meet the needs of underserved patients. As an industry leader in providing unique, accessible, and high-quality medications, Azurity leverages its integrated capabilities and vast partner network to continually expand its broad commercial product portfolio and robust late-stage pipeline. The company's patient-centric products span the cardiovascular, neurology, endocrinology, gastro-intestinal, institutional, and orphan markets, and have benefited millions of patients.

Azurity Pharmaceuticals is proud to be an inclusive workplace and an Equal Opportunity Employer. Azurity's success is attributable to our incredibly talented, dedicated team that focuses on benefiting the lives of patients by bringing the best science and commitment to quality into everything that we do. We seek highly motivated individuals with the dedication, integrity, and creative spirit needed to thrive in our organization.

Azurity is growing and standing up a new Franchise Analytics and Execution function within Commercial Operations. The Director, Franchise Analytics and Execution will shape the data strategy and analytical capabilities that underpin commercial decision-making across the Azurity portfolio. This role leads primary and secondary analytics at the national and subnational levels, owns data infrastructure and vendor relationships, and partners closely with brand teams, field leadership, and Finance to translate data into actionable insight — including contributing analytical inputs into the commercial forecasting process while pioneering the use of AI tools — including Claude and other LLM-based platforms — to accelerate reporting, modeling, and insight generation.

This role blends the traditional forecasting and secondary-analytics ownership of the function with a mandate to modernize how the team works, using AI to compress reporting cycles and unlock more self-service, decision-ready output for brand and field teams.

• Lead the design and execution of primary and secondary analytics programs supporting the full Azurity specialty portfolio at national and subnational levels.
• Own the commercial data strategy, including IQVIA data asset management, vendor relationships, and data governance standards.
• Develop and maintain BOD and Q  performance reporting packages, ensuring accuracy, timeli-ness, and executive-ready presentation.
• Partner with Finance and brand teams to provide analytical inputs and assumption support into the commercial forecast and annual brand planning cycles.
• Evaluate, pilot, and scale AI and LLM-based tools (e.g., Claude, Claude Code, Claude in Excel) to automate recurring reporting, QC checks, and dashboard generation.
• Design AI-assisted workflows that speed up forecast scenario modeling and turn raw data into first-draft executive narratives for review.
• Build and maintain subnational analytics frameworks, including territory-level performance, HCP-level activity, and market share reporting.
• Identify opportunities to enhance analytical infrastructure, including automation, data visualiza-tion, and self-service reporting capabilities.
• Manage external data vendor relationships (IQVIA, Symphony, specialty distributors), including contract scope, data delivery, and ongoing rationalization.
• Collaborate with IC & Field Strategy on targeting, segmentation, and call norm analytics.
  • Champion responsible AI use in commercial analytics — validating outputs, protecting sensitive data, and maintaining audit-ready documentation.
• Champion data accuracy and integrity across all analytical deliverables.

• Bachelor's degree required; advanced degree in analytics, statistics, business, or a related field preferred.
• 10+ years of commercial analytics experience in pharmaceutical or life sciences.
• Deep expertise in secondary data assets — IQVIA (LAAD, DDD, NPA, NSP), Symphony, specialty pharmacy data.
• Working knowledge of commercial forecast model inputs and assumptions; direct forecast ownership is not…